Clinical Trials on Lymphoid, Myeloid and Erythroid Proliferative Disease in Russian Federation

Total 300 results

Federal Research Institute of Pediatric Hematology...

Unknown

Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

Refractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia

Russian Federation
St. Petersburg State Pavlov Medical University

Active, not recruiting

PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT (PTCyRuxo)

Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Stem Cell Transplant Complications | Graft-versus-host-disease

Russian Federation
St. Petersburg State Pavlov Medical University

Completed

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Acute Myeloid Leukemia | Leukemia, Acute Lymphoblastic | Mixed-Lineage Acute Leukemias

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
St. Petersburg State Pavlov Medical University

Completed

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (FluBuBe)

Myelodysplastic Syndromes | Lymphoblastic Lymphoma | Myeloproliferative Neoplasm | Leukemia, Acute Lymphoblastic | Myeloid Leukemia, Acute | Biphenotypic Acute Leukemia

Russian Federation
Ivan S Moiseev

Completed

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Immune System Diseases | Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Acute Lymphoid Leukemia

Russian Federation
Novartis Pharmaceuticals

Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Russian Federation
Federal Research Institute of Pediatric Hematology...

Completed

Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation (45RA_NEG_DLI)

Leukemia, Myeloid, Acute | Opportunistic Infections | Graft vs Host Disease | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Bone Marrow Failure Syndromes | Immune Deficiency Disease

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myeloproliferative Neoplasm | Biphenotypic Acute Leukemia

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Malignant Lymphoma | Biphenotypic Acute Leukemia

Russian Federation
National Research Center for Hematology, Russia
St. Petersburg State Pavlov Medical University; Federal State Budgetary Institution...

Recruiting

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Refractory Acute Myeloid Leukemia | Early Relapses of Acute Myeloid Leukemia

Russian Federation
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myeloblastic Leukemia | Malignant Lymphoma | Biphenotypic Acute Leukemia

Russian Federation
Novartis Pharmaceuticals

Terminated

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib (MACS1532)

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Russian Federation
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Samara State Medical University

Recruiting

Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib

Chronic Myeloid Leukaemia

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloid Leukemia, Acute

Russian Federation
St. Petersburg State Pavlov Medical University

Terminated

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Myelodysplastic Syndromes | Leukemia, Chronic Myeloid | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Russian Federation
National Research Center for Hematology, Russia

Recruiting

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Russian Federation
Samara State Medical University

Recruiting

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Endothelial Dysfunction | Cardiotoxicity | Acute Myeloid Leukemia, Adult

Russian Federation
National Research Center for Hematology, Russia

Unknown

De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Russian Federation
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
National Research Center for Hematology, Russia

Unknown

Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment

Ph-negative Adult Acute Lymphoblastic Leukemia

Russian Federation
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

B-cell Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia, Pediatric

Russian Federation
Tomsk National Research Medical Center of the Russian...
Uppsala University

Completed

Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose

Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Adult

Russian Federation
National Research Center for Hematology, Russia
National Research Center for Hematology

Recruiting

R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Diffuse Large B-Cell Lymphoma

Russian Federation
National Research Center for Hematology, Russia

Unknown

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma (BRiF)

Follicular Lymphoma

Russian Federation
Elena N.Parovichnikova

Recruiting

R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)

Lymphoma, High-Grade

Russian Federation
Federal Research Institute of Pediatric Hematology...

Unknown

Creating a Decision Support System for the Corporate Management of Physical Therapy

Physical Activity | Physical Disability | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Brain Tumor

Russian Federation
State Budgetary Healthcare Institution, National...

Recruiting

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) (HL-Russia-1)

Hodgkin Lymphoma, Adult

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot

Childhood Acute Lymphoblastic Leukemia

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Burkitt Lymphoma | Diffuse Large B-cell Lymphoma | Primary CNS Lymphoma | Primary Mediastinal Lymphoma | Non-hodgkin Lymphoma,B Cell

Russian Federation
St. Petersburg State Pavlov Medical University

Completed

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL (BeGeRN)

Diffuse Large B Cell Lymphoma

Russian Federation
Universitätsklinikum Hamburg-Eppendorf
Clinical Trial Center North (CTC North GmbH & Co. KG); DKMS Stiftung Leben...

Recruiting

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Myelodysplastic Syndromes | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

Germany, Spain, Italy, Austria, Czechia, Finland, Russian Federation
AO GENERIUM

Recruiting

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

ALL | B-precursor Acute Lymphoblastic Leukemia | GNR-084

Russian Federation
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Russian Federation
State Budgetary Healthcare Institution, National...

Completed

Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) (Nivo-DHAP)

Hodgkin Lymphoma

Russian Federation
St. Petersburg State Pavlov Medical University

Completed

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma (NB001)

Hodgkin's Lymphoma

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

Acute Lymphoblastic Leukemia, Pediatric | ALL, Infants

Russian Federation
Ivan S Moiseev

Terminated

The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood

Myeloma Multiple

Russian Federation
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
National Medical Research Center for Cardiology...

Recruiting

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction | Amyloid Cardiomyopathy

Russian Federation
National Research Center for Hematology, Russia

Recruiting

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Primary CNS Lymphoma

Russian Federation
State Budgetary Healthcare Institution, National...

Unknown

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation (BeEAC-1)

Relapsed/Refractory Malignant Lymphomas

Russian Federation
Biointegrator LLC

Completed

Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim

Lymphoma, Follicular | Lymphoma, Non-Hodgkin

Russian Federation
St. Petersburg State Pavlov Medical University
N.N. Petrov National Medical Research Center of Oncology

Recruiting

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma (Prolgo-HL)

Hodgkin Lymphoma

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) (BASALT)

Hodgkin's Lymphoma

Russian Federation
St. Petersburg State Pavlov Medical University

Completed

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma (Nivo40)

Hodgkin Lymphoma

Russian Federation
Healthy Future

Recruiting

Gazyva Infusion Reaction Investigation (GAIRI)

Chronic Lymphocytic Leukemia

Russian Federation
Institut de Recherches Internationales Servier
ADIR, a Servier Group company; Les Laboratoires Servier (L.L.S), Russia

Completed

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

Acute Lymphoblastic Leukemia

Russian Federation
Institut de Recherches Internationales Servier
ADIR, a Servier Group company; Les Laboratoires Servier (L.L.S), Russia

Completed

A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

Acute Lymphoblastic Leukemia

Russian Federation

Clinical Trials on Lymphoid, Myeloid and Erythroid Proliferative Disease in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations